Prelude Therapeutics Announces First Quarter 2023 Financial ...

Quarterly Results - Investor Relations - Prelude Therapeutics

Q1. Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update · Form 10-Q. 2022. Q4. Prelude Therapeutics Reports Full Year 2022 ...

WILMINGTON, Del., May 08, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company ...

Prelude Therapeutics Announces First Quarter 2023 Financial ...

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update · About · Science · Clinical Trials · Investors · News · Life at ...

Prelude Therapeutics Announces First Quarter 2023 Financial

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update ; Weighted average common shares outstanding, basic and ...

News Releases - Investor Relations - Prelude Therapeutics

WILMINGTON, Del., May 31, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, ...

Prelude Therapeutics Announces First Quarter 2023 Financial ...

Today we announced Q1 financial results and operations update. “Our recent presentations at the 2023 AACR Annual Meeting highlight the meaningful progress ...

Prelude Therapeutics Announces First Quarter 2023 Financial ...

On May 8, 2023 Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, reported financial results for the first ...

Prelude Therapeutics - GlobeNewswire

November 01, 2023 16:10 ET | Source: Prelude Therapeutics, Inc. Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with ...

Prelude Therapeutics Announces Q1 2024 Financial Results and ...

Net loss for Q1 2024 was $31.4 million, or $0.42 per share, compared to a net loss of $27.7 million, or $0.58 per share, in Q1 2023. Summary

Prelude Therapeutics Reports Full Year 2023 Financial Results and ...

"In 2023, we prioritized and strengthened our pipeline to focus our resources on those programs that we believe have the highest likelihood of ...

News Releases - Investor Relations - Prelude Therapeutics

29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the ...

SEC Filing - Investor Relations - Prelude Therapeutics

On May 8, 2023, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended March 31, ...

Prelude Therapeutics Reports First Quarter 2024 Financial Results ...

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update ; Assets. Current assets: ; Current assets: Cash ...

Prelude Therapeutics Reports First Quarter 2024 Financial Results ...

“The first quarter of this year was marked by growing momentum for Prelude, led by the continued clinical progress of our two lead drug ...

Prelude Therapeutics Reports Third Quarter 2024 Financial Results ...

Prelude achieves clinical proof of concept for PRT3789 in cancer trials, secures Pfizer collaboration, and maintains strong cash position ...

News Releases - Investor Relations - Prelude Therapeutics

06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the ...

Prelude Therapeutics Incorporated (PRLD) Stock Price, Quote & News

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update ... Eight abstracts presented at AACR 2023 demonstrate progress of the ...

Prelude Therapeutics Announces Second Quarter 2023 Financial ...

Four lead programs on track to deliver clinical data and to inform future development plans Recent equity financing extends cash runway into ...

Prelude Therapeutics Reports Third Quarter 2024 Financial Results ...

Cash, Cash Equivalents, and Marketable securities: Cash, cash equivalents and marketable securities as of September 30, 2024 were $153.6 million ...

Prelude Therapeutics Incorporated (NASDAQ:PRLD) to Post Q1 ...

Jefferies Financial Group also issued estimates for Prelude Therapeutics' Q3 2023 earnings at ($0.64) EPS, FY2023 earnings at ($2.55) EPS, FY2024 earnings at ($ ...